MLTX on Nasdaq
MoonLake Immunotherapeutics
Pharmaceutical preparations company in the Cayman Islands.
Price unavailable
Last updated Oct 18, 2026.
Overview
-$227.3MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | -$202.9M | -$112.8M | -$31.8M |
| General and administrative | -$42.0M | -$30.3M | -$22.3M |
| Total operating expenses | -$244.8M | -$143.1M | -$54.1M |
| Operating loss | -$244.8M | -$143.1M | -$54.1M |
| Interest expense | -$7.2M | $0 | $0 |
| Other income, net | $22.4M | $22.1M | $10.1M |
| Loss before income tax | -$229.7M | -$121.0M | -$44.0M |
| Income tax expense | -$611.0K | -$282.0K | -$94.0K |
| Net loss | -$230.3M | -$121.2M | -$44.1M |
| Of which: net loss attributable to controlling interests shareholders | -$227.3M | -$118.9M | -$36.0M |
| Of which: net loss attributable to noncontrolling interests shareholders | -$3.0M | -$2.3M | -$8.1M |
| Net unrealized gain (loss) on marketable securities and short-term investments | -$5.1M | $2.7M | $2.3M |
| Actuarial gain (loss) on employee benefit plans | $641.0K | -$87.0K | -$336.0K |
| Other comprehensive income (loss) | -$4.5M | $2.6M | $2.0M |
| Comprehensive loss | -$234.8M | -$118.6M | -$42.1M |
| Comprehensive loss attributable to controlling interests shareholders | -$231.7M | -$116.4M | -$34.5M |
| Comprehensive loss attributable to noncontrolling interests | -$3.1M | -$2.3M | -$7.6M |
| Weighted-average number of shares, basic (in shares) | 64.5M shares | 62.9M shares | 49.1M shares |
| Weighted-average number of shares, diluted (in shares) | 64.5M shares | 62.9M shares | 49.1M shares |
| Basic net loss per share attributable to controlling interest shareholders (USD per share) | -$3.53 | -$1.89 | -$0.73 |
| Diluted net loss per share attributable to controlling interest shareholders (USD per share) | -$3.53 | -$1.89 | -$0.73 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $334.5M | $180.4M | ||
| Short-term marketable debt securities | $59.5M | $267.6M | ||
| Other receivables | $4.9M | $2.8M | ||
| Prepaid expenses | $22.9M | $23.4M | ||
| Total current assets | $421.7M | $474.3M | ||
| Operating lease right-of-use assets | $1.6M | $2.9M | ||
| Property and equipment, net | $577.0K | $722.0K | ||
| Other non-current assets | $596.0K | $0 | ||
| Total non-current assets | $2.7M | $3.6M | ||
| Total assets | $424.4M | $477.9M | ||
| Trade and other payables | $29.6M | $9.0M | ||
| Accrued expenses and other current liabilities | $14.7M | $12.1M | ||
| Short-term portion of operating lease liabilities | $1.2M | $1.4M | ||
| Total current liabilities | $45.5M | $22.5M | ||
| Long-term debt | $74.1M | $0 | ||
| Long-term portion of operating lease liabilities | $374.0K | $1.5M | ||
| Pension liability | $0 | $621.0K | ||
| Total non-current liabilities | $74.5M | $2.1M | ||
| Total liabilities | $120.0M | $24.5M | ||
| Additional paid-in capital | $766.8M | $677.4M | ||
| Accumulated deficit | -$462.9M | -$235.6M | ||
| Accumulated other comprehensive income | $604.0K | $5.0M | ||
| Total shareholders equity | $304.5M | $446.8M | ||
| Noncontrolling interests | $0 | $6.6M | ||
| Total equity | $304.5M | $453.4M | $513.5M | $68.8M |
| Total liabilities and equity | $424.4M | $477.9M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $334.5M | $180.4M | ||
| Short-term marketable debt securities | $59.5M | $267.6M | ||
| Other receivables | $4.9M | $2.8M | ||
| Prepaid expenses | $22.9M | $23.4M | ||
| Total current assets | $421.7M | $474.3M | ||
| Operating lease right-of-use assets | $1.6M | $2.9M | ||
| Property and equipment, net | $577.0K | $722.0K | ||
| Other non-current assets | $596.0K | $0 | ||
| Total non-current assets | $2.7M | $3.6M | ||
| Total assets | $424.4M | $477.9M | ||
| Trade and other payables | $29.6M | $9.0M | ||
| Accrued expenses and other current liabilities | $14.7M | $12.1M | ||
| Short-term portion of operating lease liabilities | $1.2M | $1.4M | ||
| Total current liabilities | $45.5M | $22.5M | ||
| Long-term debt | $74.1M | $0 | ||
| Long-term portion of operating lease liabilities | $374.0K | $1.5M | ||
| Pension liability | $0 | $621.0K | ||
| Total non-current liabilities | $74.5M | $2.1M | ||
| Total liabilities | $120.0M | $24.5M | ||
| Additional paid-in capital | $766.8M | $677.4M | ||
| Accumulated deficit | -$462.9M | -$235.6M | ||
| Accumulated other comprehensive income | $604.0K | $5.0M | ||
| Total shareholders equity | $304.5M | $446.8M | ||
| Noncontrolling interests | $0 | $6.6M | ||
| Total equity | $304.5M | $453.4M | $513.5M | $68.8M |
| Total liabilities and equity | $424.4M | $477.9M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$230.3M | -$121.2M | -$44.1M |
| Depreciation and amortization | $2.6M | $1.4M | $370.0K |
| Share-based compensation expense | $12.9M | $7.3M | $7.1M |
| Net periodic pension benefit (gain) loss for the qualified pension plan | -$58.0K | $1.0K | -$85.0K |
| Other non-cash items | -$1.0M | -$227.0K | $128.0K |
| Other receivables | -$2.0M | -$1.8M | -$840.0K |
| Operating lease right-of-use assets | $0 | -$6.0K | -$66.0K |
| Prepaid expenses | $561.0K | -$12.9M | -$6.3M |
| Other non-current assets | -$587.0K | $0 | $0 |
| Trade and other payables | $20.6M | $7.2M | $1.6M |
| Operating lease liabilities | -$1.2M | -$1.4M | -$222.0K |
| Accrued expenses and other current liabilities | $2.6M | $5.2M | -$327.0K |
| Net cash flow used in operating activities | -$196.0M | -$116.6M | -$42.8M |
| Purchase of short-term marketable debt securities | -$265.4M | -$350.3M | -$175.7M |
| Proceeds from maturities of short-term marketable debt securities | $468.4M | $145.2M | $150.8M |
| Purchase of property and equipment | -$35.0K | -$520.0K | -$284.0K |
| Net cash flow provided by (used in) investing activities | $203.0M | -$205.6M | -$25.2M |
| Proceeds from long-term debt, net of issuance costs | $73.0M | $0 | $0 |
| Issuance of Class A Ordinary Shares, net of transaction costs | $72.4M | $52.5M | $482.5M |
| Stamp duty on capital injection from MoonLake to MoonLake AG | $0 | -$1.5M | -$2.8M |
| Net cash flow provided by financing activities | $146.0M | $51.3M | $479.7M |
| Effect of movements in exchange rates on cash held | $1.1M | $128.0K | -$76.0K |
| Net change in cash and cash equivalents | $154.1M | -$270.7M | $411.7M |
| Cash paid for interest | $5.1M | $0 | $0 |
| Non-cash operating lease right-of-use assets obtained in exchange for lease obligations | $0 | $555.0K | $3.6M |
No quarter-by-quarter statement was filed.
Leadership
Who has led MoonLake Immunotherapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
2025
- Chief executive officerDa Silva Jorge Santos Apr 15, 2022 to now11
- Chief executive officerBihua Chen Oct 19, 2020 to Oct 22, 202012
- ChairBihua Chen Oct 19, 2020 to Oct 22, 202012
- Chief financial officerMatthias Bodenstedt Apr 15, 2022 to now13
- Chief financial officerJay Scollins Oct 19, 2020 to Oct 19, 202014
Board members and other officers (10)
- Chief Scientific OfficerKristian Reich Apr 15, 2022 to now15
- Board memberAndrew John Phillips Apr 15, 2022 to now16
- Board memberCatherine Moukheibir Apr 15, 2022 to now17
- Board memberDa Silva Jorge Santos Apr 15, 2022 to now11
- Board memberKara Lassen Apr 15, 2022 to Apr 15, 202218
- Board memberMark N. Lampert Apr 15, 2022 to now19
- Board memberRamnik Xavier Apr 15, 2022 to now20
- Board memberSpike Loy Apr 15, 2022 to now21
- Board memberJohn P. Schmid Oct 19, 2020 to Oct 19, 202022
- Board memberNancy T. Chang Oct 19, 2020 to Oct 19, 202023
Former names
- Helix Acquisition CorpAug 28, 2020 to Mar 31, 20223
Timeline
Filings
293 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 51 major events, 89 insider forms, 38 large holders, 92 other. The latest 20:
- Sep 30, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 2026S-8 REGISTRATION STATEMENT EDGAR
- Aug 10, 2026S-3ASR REGISTRATION STATEMENT EDGAR
- Aug 10, 20268-K CURRENT REPORT EDGAR
- Jul 29, 20264 EDGAR
- Jul 23, 20264 EDGAR
- Jul 21, 20264 EDGAR
- Jul 20, 20264 EDGAR
- Jul 15, 2026144 EDGAR
- Jul 15, 20268-K CURRENT REPORT EDGAR
- Jul 13, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jun 30, 2026144 EDGAR
- Jun 29, 2026SCHEDULE 13D/A EDGAR
- Jun 25, 20268-K CURRENT REPORT EDGAR
- Jun 24, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
The 293 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 38 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Jun 29, 2026SCHEDULE 13D/A
- May 15, 2026SCHEDULE 13G/A
- Apr 2, 2026SCHEDULE 13D/A
- Feb 17, 2026SCHEDULE 13G
- Nov 14, 2025SCHEDULE 13G/A
- Nov 12, 2025SCHEDULE 13G
- Nov 10, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Bvf Inc/il | 16,001,284 | $311.5M | 8.0% | No change |
| Deep Track Capital, LP | 6,999,025 | $136.3M | 2.0% | +590,162 |
| D. E. Shaw & Co., Inc. | 3,365,507 | $65.5M | 0.0% | +974,846 |
| Cormorant Asset Management, LP | 3,205,433 | $62.4M | 3.2% | −1,275,000 |
| Jupiter Topco LLC | 3,085,906 | $60.1M | 0.0% | New |
| Logos Global Management LP | 2,675,000 | $52.1M | 2.2% | +1,175,000 |
| Weiss Asset Management LP | 2,581,813 | $50.3M | 0.7% | +873,485 |
| Citadel Advisors LLC | 1,972,893 | $38.4M | 0.0% | +649,165 |
| Two Sigma Investments, LP | 1,715,349 | $33.4M | 0.0% | +593,037 |
| Mpm Bioimpact LLC | 1,606,967 | $31.3M | 1.9% | −204,115 |
| Jpmorgan Chase & Co | 1,386,422 | $27.6M | 0.0% | +297,908 |
| Vivo Capital, LLC | 1,400,000 | $27.3M | 2.5% | +400,000 |
| Point72 Asset Management, L.P. | 1,158,732 | $22.6M | 0.0% | −209,786 |
| BlackRock, Inc. | 1,094,791 | $21.3M | 0.0% | +72,940 |
| Balyasny Asset Management L.P. | 912,715 | $17.8M | 0.0% | −152,895 |
| Great Point Partners LLC | 855,813 | $16.7M | 3.9% | +355,813 |
| Jane Street Group, LLC | 853,386 | $16.6M | 0.0% | +399,761 |
| Candriam S.C.A. | 769,766 | $15.0M | 0.1% | −48,360 |
| Bank Of America Corp /de/ | 751,897 | $14.6M | 0.0% | +27,103 |
| Arrowstreet Capital, Limited Partnership | 750,777 | $14.6M | 0.0% | +680,637 |
| Trails Edge Capital Partners, LP | 750,000 | $14.6M | 2.3% | New |
| Renaissance Technologies LLC | 643,268 | $12.5M | 0.0% | +366,496 |
| Millennium Management LLC | 636,187 | $12.4M | 0.0% | +60,095 |
| Morgan Stanley | 563,602 | $11.0M | 0.0% | −50,880 |
| Marshall Wace, Llp | 550,351 | $10.7M | 0.0% | +439,020 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARBihua Chen, Chief executive officer
- 13
- 14
- 15
- 16SEC EDGARAndrew John Phillips, Board member
- 17SEC EDGARCatherine Moukheibir, Board member
- 18SEC EDGARKara Lassen, Board member
- 19SEC EDGARMark N. Lampert, Board member
- 20SEC EDGARRamnik Xavier, Board member
- 21SEC EDGARSpike Loy, Board member
- 22SEC EDGARJohn P. Schmid, Board member
- 23SEC EDGARNancy T. Chang, Board member